The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...
Puretz, a 29-year old real estate investor, is facing a sentence of five years in prison for his role in a ...
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
By Bill [email protected] Coach Simon Morefield’s Truman Patriots were holding their own in a conference ...
Eli Lilly just gave investors several reasons to cheer.
The Missouri Tigers wasted no time revitalizing their linebacker room via the transfer portal, with two of their first four ...
Two Super Bowl victories and two Super Bowl MVPs, but a .500 record and 244 interceptions. Whatever his legacy is, Manning is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback